OnCo
technologiesTechnologyPhase 1

FLASH radiotherapy

Delivering an entire dose in under a second, which in animals spares healthy tissue while still killing the tumour.

Ultra-high dose rates (>40 Gy/s) reduce normal-tissue toxicity in preclinical models. First-in-human trials (FAST-01/02 with protons, Varian; electron trials in Lausanne) show feasibility. Mechanism (oxygen depletion, radical recombination) is debated and the clinical effect unproven.

Schematic · not to scale
> 40 Gy/s, < 1 s · Same tumour kill · Normal tissue spared

How it works

Dose delivered in milliseconds rather than minutes; differential normal-tissue sparing.

Strengths
  • Potential to widen therapeutic window dramatically
Limitations
  • Unproven in humans
  • Hardware constraints for deep tumours

Latest papers

top
Literature trend167 papers in the last 12 months+45% vs prior 12How this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"FLASH radiotherapy" OR ABSTRACT:"FLASH radiotherapy" OR TITLE:"ultra-high dose rate radiotherapy" OR ABSTRACT:"ultra-high dose rate radiotherapy"). Results are unfiltered search hits about FLASH radiotherapy, not a curated reading list.

Connected

14top